利奈唑啉
医学
肺结核
不利影响
结核分枝杆菌
药品
抗生素
药理学
重症监护医学
微生物学
病理
细菌
万古霉素
金黄色葡萄球菌
生物
遗传学
作者
Dionysia Fermeli,Theodoros Marantos,Alexandros Leonidas Liarakos,George Panayiotakopoulos,Vasileios Dedes,Georgios I Panoutsopoulos
出处
期刊:Folia Medica
[Pensoft Publishers]
日期:2020-09-30
卷期号:62 (3): 444-452
被引量:4
标识
DOI:10.3897/folmed.62.e48742
摘要
Tuberculosis is a severe, infectious disease caused by Mycobacterium tuberculosis . The aim of this review was to present the efficacy of linezolid as an agent against multidrug and extensively drug-resistant tuberculosis as gathered from many recent research studies. Linezolid seems to have strongly the potential of being used as an anti-tuberculosis agent because it blocks bacterial ribosomal protein synthesis. Nevertheless caution is required because of the adverse effects it causes, especially when the linezolid daily dosage exceeds 600 mg. The most severe adverse effects include anemia, peripheral neuropathy, optic neuropathy and thrombocytopenia. Still, more trials and research need to be done in order to gather more information and value the cost-benefit dosage of the treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI